ArticleTanaffos2024
Could We Predict Chronic Obstructive Pulmonary Disease Exacerbation Based on Neutrophil to Lymphocyte Count Ratio (NLR)?
Article in Tanaffos, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The neutrophil to lymphocyte ratio (NLR) is an inflammatory biomarker that could be used as an indicator of systemic inflammation (sepsis) and could also be used to predict the prognosis of some diseases, such as solid cancer, community pneumonia, as well as cardiovascular diseases. This study aimed to assess the potential role of NLR and eosinopenia in patients with acute exacerbation of COPD (AECOPD) compared to those in the stable phase of the disease. Materials and Methods: NLR was assessed and compared in patients with AECOPD (n=92) and those in the stable phase of COPD (n=240). Patients under the age of 18, those who used inhaled corticosteroids, or those with any condition affecting the neutrophil (NEU) or lymphocyte (LYM) count in peripheral blood, such as hematological illnesses, pregnancy, or a history of medication use, were excluded from the study. The NLR was determined using NEU and LYM counts from regular blood tests. We defined the cut-off value for eosinopenia as the percentage of eosinophils≤1%. Results: We included 332 inpatients with COPD diagnosed in our hospital from April to October 2021. AECOPD was discovered in 92 patients. Patients with exacerbation had considerably lower levels of BMI (24.32±4.38 vs 26±4.02), FEV1/FVC (55.38±9.14 vs 60.54±6.95), and NLR ratio, except for the first NLR quartile (39.13 %), the second was 20.65 %, the third was 18.48 %, and the fourth was 21.74 %. Eosinopenia was detected in 79 (85.87 %) of AECOPD patients. Conclusion: We found that the NLR was lower in patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD), except for those in the first NLR quartile.
Indexed as
Identifiers
40704345PMC12281342What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.